Avinger (NASDAQ:AVGR) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Avinger (NASDAQ:AVGR) in a note issued to investors on Thursday. The brokerage set a “hold” rating on the medical device company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Avinger in a research note on Thursday, March 21st.

Avinger Price Performance

Shares of NASDAQ:AVGR traded up $0.06 during midday trading on Thursday, reaching $3.90. The company’s stock had a trading volume of 10,223 shares, compared to its average volume of 13,949. The business has a 50 day moving average price of $3.46 and a 200 day moving average price of $3.29. Avinger has a 1 year low of $2.50 and a 1 year high of $18.00.

Avinger (NASDAQ:AVGR) last released its earnings results on Wednesday, March 20th. The medical device company reported ($3.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.64 by ($4.57). The company had revenue of $1.91 million for the quarter, compared to analysts’ expectations of $2.52 million. Equities research analysts forecast that Avinger will post -2.08 EPS for the current year.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.